Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $380.45 million. The enterprise value is $342.59 million.
Important Dates
The next estimated earnings date is Monday, March 9, 2026, after market close.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 242.33 million shares outstanding. The number of shares has increased by 25.54% in one year.
| Current Share Class | 242.33M |
| Shares Outstanding | 242.33M |
| Shares Change (YoY) | +25.54% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 5.13% |
| Owned by Institutions (%) | 18.89% |
| Float | 180.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.73 |
| Forward PS | 21.01 |
| PB Ratio | 16.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.50 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -157.75% and return on invested capital (ROIC) is -27.95%.
| Return on Equity (ROE) | -157.75% |
| Return on Assets (ROA) | -13.65% |
| Return on Invested Capital (ROIC) | -27.95% |
| Return on Capital Employed (ROCE) | -25.34% |
| Weighted Average Cost of Capital (WACC) | 13.77% |
| Revenue Per Employee | $140,468 |
| Profits Per Employee | -$878,662 |
| Employee Count | 77 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.83% in the last 52 weeks. The beta is 1.75, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | +150.83% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 42.04 |
| Average Volume (20 Days) | 936,696 |
Short Selling Information
The latest short interest is 24.64 million, so 10.17% of the outstanding shares have been sold short.
| Short Interest | 24.64M |
| Short Previous Month | 22.84M |
| Short % of Shares Out | 10.17% |
| Short % of Float | 13.66% |
| Short Ratio (days to cover) | 19.03 |
Income Statement
In the last 12 months, LCTX had revenue of $10.82 million and -$67.66 million in losses. Loss per share was -$0.29.
| Revenue | 10.82M |
| Gross Profit | -1.95M |
| Operating Income | -20.34M |
| Pretax Income | -67.51M |
| Net Income | -67.66M |
| EBITDA | -19.68M |
| EBIT | -20.34M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $40.49 million in cash and $2.62 million in debt, with a net cash position of $37.87 million or $0.16 per share.
| Cash & Cash Equivalents | 40.49M |
| Total Debt | 2.62M |
| Net Cash | 37.87M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 20.80M |
| Book Value Per Share | 0.10 |
| Working Capital | 32.88M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.39 million and capital expenditures -$488,000, giving a free cash flow of -$20.88 million.
| Operating Cash Flow | -20.39M |
| Capital Expenditures | -488,000 |
| Free Cash Flow | -20.88M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
| Gross Margin | -17.98% |
| Operating Margin | -188.06% |
| Pretax Margin | -624.16% |
| Profit Margin | n/a |
| EBITDA Margin | -181.92% |
| EBIT Margin | -188.06% |
| FCF Margin | n/a |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.54% |
| Shareholder Yield | -25.54% |
| Earnings Yield | -17.78% |
| FCF Yield | -5.49% |
Analyst Forecast
The average price target for LCTX is $4.67, which is 197.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 197.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 60.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6 |
| Piotroski F-Score | 3 |
